Communiqués BioAtla, Inc.

Actions

BCAB

US09077B1044

Temps réel estimé Cboe BZX Autres places de cotation 16:33:26 26/06/2024			Varia. 5j.	Varia. 1 janv.
1,595 ^USD	+4,25%		+14,84%	-33,94%

23/05	BioAtla, Inc. Présente les données de l'étude clinique de phase 1 d'Evalstotug démontrant un bénéfice clinique lors de la prochaine réunion annuelle de l'American Society of Clinical Oncology (ASCO) qui se tiendra en 2024.	CI
15/05	Les fonds négociés en bourse sont en hausse, les contrats à terme sur actions sont mitigés avant la cloche de mercredi, en prévision des données clés sur l'inflation et le commerce de détail.	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioAtla to Participate in the Jefferies Global Healthcare Conference	29/05	AQ
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	23/05	AQ
BioAtla : BCAB_Corp_Update_May 2024_FINALv3	14/05	PU
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress	14/05	AQ
BioAtla to Participate in the Citizens JMP Life Sciences Conference	08/05	AQ
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024	07/05	AQ
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors	06/05	AQ
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04	AQ
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress	26/03	AQ
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024	19/03	AQ
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting	07/03	AQ
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	20/12	GL
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types	13/12	AQ
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023	06/12	AQ
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event	05/12	GL
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event	05/12	AQ
BioAtla to Participate in the JMP Securities Hematology and Oncology Summit	30/11	GL
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC	28/11	GL
BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress	07/11	GL
BioAtla to Participate in the Jefferies London Healthcare Conference	06/11	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués BioAtla, Inc.

Actions

BCAB

US09077B1044

Communiqués

Filtres